Noticias y vídeos - EIGER BIOPHARMACEUTICALS INC. - Página 2

EIGER BIOPHARMACEUTICALS, INC. (NASDAQ: EIGR) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) PR Newswire NEW YORK, Jan. 5, 2023 Did you lose money on investments in Eiger BioPharmaceuticals, Inc.? If so, please visit Eiger BioPharmaceuticals, Inc. Shareholder Class Action Lawsuit or contact Peter Allocco at (212) 951-2030 or...

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eiger BioPharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2023 - (NASDAQ: EIGR) PR Newswire NEW YORK, Jan. 4, 2023 NEW YORK , Jan. 4, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eiger BioPharmaceuticals, Inc.. Shareholders who purchased shares of EIGR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action - EIGR PR Newswire NEW YORK, Jan. 2, 2023 NEW YORK , Jan. 2, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) between March 10, 2021 and October 4, 2022, both dates inclusive (the "Class Period"), of the...

EIGR Investors Have Opportunity to Lead Eiger BioPharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire LOS ANGELES, Dec. 29, 2022 LOS ANGELES , Dec. 29, 2022 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR ). Class Period: March 10, 2021 – October 4, 2022 Lead Plaintiff Deadline: January 9,...

EIGR LAWSUIT ALERT: Levi & Korsinsky Notifies Eiger BioPharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire NEW YORK, Dec. 29, 2022 NEW YORK , Dec. 29, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Eiger investors who were adversely affected by alleged securities...

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eiger BioPharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2023 - (NASDAQ: EIGR) PR Newswire NEW YORK, Dec. 28, 2022 NEW YORK , Dec. 28, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eiger BioPharmaceuticals, Inc.. Shareholders who purchased shares of EIGR during the class period listed are encouraged to contact the firm regarding possible lead...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eiger BioPharmaceuticals, Inc., of Class Action Lawsuit and Upcoming Deadline - EIGR PR Newswire NEW YORK, Dec. 26, 2022 NEW YORK , Dec. 26, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), and certain officers. The class action, filed in the United States District Court for the Northern District of California...

ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - EIGR PR Newswire NEW YORK, Dec. 23, 2022 NEW YORK , Dec. 23, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) between March 10, 2021 and October 4, 2022, both dates inclusive (the "Class Period"), of the important January 9,...

EIGR LAWSUIT ALERT: Levi & Korsinsky Notifies Eiger BioPharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline PR Newswire NEW YORK, Dec. 22, 2022 NEW YORK , Dec. 22, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Eiger investors who were adversely affected by alleged securities...

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eiger BioPharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2023 - (NASDAQ: EIGR) PR Newswire NEW YORK, Dec. 21, 2022 NEW YORK , Dec. 21, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eiger BioPharmaceuticals, Inc.. Shareholders who purchased shares of EIGR during the class period listed are encouraged to contact the firm regarding possible lead...

EIGR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 9, 2023 in the Class Action Filed on Behalf of Eiger BioPharmaceuticals, Inc. Shareholders PR Newswire NEW YORK, Dec. 20, 2022 NEW YORK , Dec. 20, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) alleging that the Company violated federal securities laws. Class Period: March 10, 2021 to October 4,...

RM LAW Announces Class Action Lawsuit Against Eiger Biopharmaceuticals, Inc. PR Newswire BERWYN, Pa., Dec. 19, 2022 BERWYN, Pa. , Dec. 19, 2022 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Eiger Biopharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR) securities during the period from March 10, 2021 through October 4, 2022 , inclusive (the "Class Period"). Eiger shareholders may, no later than...

ROSEN, A TOP RANKED LAW FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - EIGR PR Newswire NEW YORK, Dec. 16, 2022 NEW YORK , Dec. 16, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) between March 10, 2021 and October 4, 2022, both dates inclusive (the "Class Period"), of the important...

Eiger BioPharmaceuticals, Inc. (“Eiger” or “the company”) (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, and its Board of Directors today announced that David A. Cory has resigned as President, Chief Executive Officer and member of the Board of Directors, effective immediately. David Apelian, MD, PhD, MBA, Senior Clinical Advisor and member of the Board of...

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eiger BioPharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2023 - (NASDAQ: EIGR) PR Newswire NEW YORK, Dec. 14, 2022 NEW YORK , Dec. 14, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eiger BioPharmaceuticals, Inc.. Shareholders who purchased shares of EIGR during the class period listed are encouraged to contact the firm regarding possible lead...

EIGR ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of January 9, 2023 in the Class Action Filed on Behalf of Eiger BioPharmaceuticals, Inc. Shareholders PR Newswire NEW YORK, Dec. 13, 2022 NEW YORK , Dec. 13, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) alleging that the Company violated federal securities laws. Class Period: March 10, 2021 to October 4,...

EIGR Investors Have Opportunity to Lead Eiger BioPharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire LOS ANGELES, Dec. 13, 2022 LOS ANGELES , Dec. 13, 2022 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Eiger BioPharmaceuticals, Inc. ("Eiger" or the "Company") (NASDAQ: EIGR ). Class Period: March 10, 2021 – October 4, 2022 Lead Plaintiff Deadline: January 9, 2023...

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Eiger BioPharmaceuticals, Inc., of Class Action Lawsuit and Upcoming Deadline - EIGR PR Newswire NEW YORK, Dec. 13, 2022 NEW YORK , Dec. 13, 2022 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), and certain officers. The class action, filed in the United States District Court for the Northern District of California...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR) between March 10, 2021 and October 4, 2022, both dates inclusive (the “Class Period”), of the important January 9, 2023 lead plaintiff deadline . SO WHAT: If you purchased Eiger securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO...

LOS ANGELES, CA / ACCESSWIRE / December 12, 2022 / The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Eiger BioPharmaceuticals, Inc. ("Eiger" or "the Company") (NASDAQ: EIGR ) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 10, 2021 and October 4,...